

Vimpat® (lacosamide) – First-time generic

- On March 21, 2022, Tris Pharma launched <u>Indoco Remedies</u>, and <u>Alembic</u>, <u>Amneal</u> and Glenmark launched AB-rated generic versions of UCB's Vimpat (lacosamide) tablets.
 - In addition, on March 17, 2022, FDA granted approval to AB-rated generic versions of Vimpat to <u>Hetero</u>, <u>MSN Laboratories</u>, <u>ScieGen</u> and <u>Sun Pharmaceuticals</u>. These manufacturers may launch generic Vimpat at any time.
- Vimpat is approved for the treatment of partial-onset seizures in patients 1 month of age and older, and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
- Vimpat is also available as a brand oral solution and injection that carry the same indications as the tablets.
- According to IQVIA, Vimpat tablets had annual sales of \$1.7 billion as of January 2022.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.